A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies
Status: Active_not_recruiting
Location: See all (13) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY
A Study of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Advanced or Metastatic Malignancies
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Currently receiving sitravatinib single- agent or in combination with other therapeutic agent(s) in another Mirati- sponsored protocol
• Currently tolerating the treatment regimen in the parent protocol
• Experiencing clinical benefit with or without prior radiographic progression from the treatment regimen in the parent protocol in the opinion of the investigator and the investigator determines that continuing treatment is in the patient's best interest
Locations
United States
Colorado
Local Institution - 516-014-021
Littleton
Indiana
Local Institution - 516-014-029
Goshen
Massachusetts
Local Institution - 516-014-002
Boston
Michigan
Local Institution - 516-014-014
Detroit
Minnesota
Local Institution - 516-014-005
Minneapolis
Nebraska
Local Institution - 516-014-018
Omaha
New York
Local Institution - 516-014-011
Albany
Local Institution - 516-014-016
New York
Ohio
Local Institution - 516-014-004
Columbus
Texas
Local Institution - 516-014-001
Austin
Local Institution - 516-014-006
Denison
Local Institution - 516-014-013
Houston
Virginia
Local Institution - 516-014-027
Fairfax
Time Frame
Start Date: 2021-06-30
Completion Date: 2025-04-19
Participants
Target number of participants: 55
Treatments
Experimental: Phase 2/3: Open label extension of parent study
The current study is designed to allow continued access to sitravatinib and to evaluate the safety and tolerability of sitravatinib alone or in combination with other anticancer therapies in patients who are deriving clinical benefit in a previous parent clinical trial.
Authors
Sponsors
Leads: Mirati Therapeutics Inc.